Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELENE: Ibrutinib + BR or R-CHOP in R/R iNHL
NCT01974440Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2014
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of ibrutinib in follicular lymphoma (FL), marginal zone lymphoma (MZL), sponsored by Janssen Pharmaceutical. Started Jan 2014; status: completed.
02
Drugs
ibrutinib
03
Conditions
follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT01974440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01974440.